Last updated: September 1, 2026
Amiloride hydrochloride is a mature, low-cost potassium-sparing diuretic with minimal branded revenue, no meaningful biologic or biosimilar exposure, and limited patent protection. Its commercial value is concentrated in generic tablet supply, hospital and retail formulary access, and combination use with thiazide or loop diuretics. Financial growth is likely to remain limited, while supply continuity and manufacturing economics are the main market variables.
What is the current FDA status of amiloride hydrochloride?
Amiloride hydrochloride is an FDA-approved potassium-sparing diuretic marketed primarily as an oral tablet. It is indicated as an adjunct to thiazide or other kaliuretic diuretics for hypertension, congestive heart failure, and edema associated with cirrhosis.[1]
| Attribute |
Status |
| Active ingredient |
Amiloride hydrochloride |
| Drug class |
Potassium-sparing diuretic |
| Primary dosage form |
Oral tablet |
| Common strength |
5 mg |
| Combination product |
Amiloride hydrochloride and hydrochlorothiazide |
| Regulatory pathway |
Legacy NDA and multiple ANDA products |
| FDA exclusivity |
Expired |
| Biosimilar pathway |
Not applicable |
| Prescription status |
Prescription-only |
| Primary commercial market |
U.S. generic retail and institutional channels |
The original branded product, Midamor, was developed as a potassium-sparing alternative to more potent diuretics. Current U.S. supply is predominantly generic. FDA labeling identifies amiloride as an adjunctive agent rather than a preferred stand-alone diuretic in most treatment settings.[1]
When did amiloride hydrochloride lose exclusivity?
Amiloride hydrochloride lost meaningful market exclusivity decades ago. The product originated in the 1960s, and any original composition, formulation, or use patents have expired. Generic competition has existed for many years.
There is no current commercial exclusivity comparable to the market protection attached to newer small-molecule drugs. The product is outside the practical protection period for:
- New chemical entity exclusivity
- Original composition-of-matter patents
- FDA orphan-drug exclusivity
- Pediatric exclusivity linked to a protected product
- Market exclusivity associated with a novel delivery system
The economic consequence is a commodity-like market. Manufacturers compete primarily on manufacturing cost, contract access, wholesaler relationships, supply reliability, and regulatory compliance.
What patents protect amiloride hydrochloride?
No commercially material active patent barrier is apparent for standalone amiloride hydrochloride tablets in the U.S. generic market. The original active-ingredient and product patents are historical rather than relevant to current generic entry.
| Patent category |
Current commercial relevance |
| Composition-of-matter patent |
Expired |
| Original tablet formulation patent |
Expired or commercially immaterial |
| Method-of-use patent |
No material barrier identified |
| Combination-product patent |
Historical protection expired |
| Device or delivery-system patent |
Not relevant to standard tablets |
| Manufacturing-process patent |
Potentially proprietary but unlikely to block ordinary generic entry |
The absence of meaningful patent protection does not eliminate all intellectual-property issues. Manufacturers may still protect manufacturing processes, impurity-control methods, supplier relationships, analytical methods, trademarks, packaging, and regulatory know-how. Those rights generally do not prevent other manufacturers from producing conventional amiloride hydrochloride tablets when the relevant FDA pathway is available.
How many patents cover amiloride hydrochloride?
For commercial purposes, the number of active patents that materially restrict generic sales is effectively zero for the standard U.S. tablet product. FDA Orange Book review is the relevant regulatory test for listed patents associated with approved products.[2]
The patent landscape differs from products with multiple active formulation and method-of-use patents. Amiloride hydrochloride does not have a current patent estate comparable to branded cardiovascular, oncology, immunology, or specialty pharmaceutical products.
A manufacturer entering the market would still need to address:
- FDA approval requirements for the relevant dosage form.
- Bioequivalence or other applicable pharmaceutical-equivalence requirements.
- Current good manufacturing practice compliance.
- Drug master file and active pharmaceutical ingredient sourcing.
- Labeling consistency.
- Potential product-liability and quality-system risks.
These are regulatory and operational barriers rather than patent barriers.
What is the Orange Book status of amiloride hydrochloride?
The Orange Book identifies approved prescription drug products and therapeutic-equivalence information. Generic amiloride hydrochloride tablets are evaluated through abbreviated new drug applications and may receive an “AB” therapeutic-equivalence rating when they meet FDA requirements for pharmaceutical equivalence and bioequivalence.[2]
The commercially relevant Orange Book position is:
- The reference product is a legacy FDA-approved product.
- Generic tablets are eligible for ANDA approval.
- No active patent term is expected to delay ordinary generic entry.
- Paragraph IV litigation is not a central market issue for this product.
- Regulatory status is determined more by product availability and manufacturing compliance than by exclusivity.
Orange Book status can change as FDA updates product listings, withdrawal codes, therapeutic-equivalence ratings, and patent records. Companies conducting a transaction or launch assessment should rely on the contemporaneous FDA listing rather than historical product databases.
Which companies manufacture or market amiloride hydrochloride?
The U.S. market has historically included multiple generic manufacturers and authorized distributors. The specific supplier set changes as companies discontinue low-volume products, transfer ANDAs, or rely on contract manufacturing.
Common commercial participants in generic oral solid-dose markets have included companies such as:
- Amneal Pharmaceuticals
- AvKARE
- Camber Pharmaceuticals
- Major Pharmaceuticals
- Par Pharmaceutical
- Rising Pharmaceuticals
- Sandoz
- Solco Healthcare
- Teva Pharmaceuticals
- Zydus Pharmaceuticals
The presence of a company in a historical product directory does not establish current commercial availability. NDC status, wholesaler inventory, FDA drug listings, and manufacturer product catalogs are more reliable indicators of active supply.[3]
What is the market size for amiloride hydrochloride?
Public sources do not generally report a reliable, standalone U.S. revenue figure for amiloride hydrochloride. Manufacturers report generic portfolios in aggregate, and prescription databases often combine products across manufacturers, strengths, channels, and combination therapies.
The market is best characterized as:
- Low revenue per prescription
- Mature or declining unit demand
- High generic substitution
- Limited pricing power
- Small contribution to manufacturer revenue
- Greater importance in formulary completeness than in revenue growth
Amiloride is inexpensive compared with newer antihypertensive and heart-failure therapies. Its financial value is therefore driven by prescription volume rather than price expansion. The product can generate stable cash flow for a manufacturer with an efficient supply chain, but it is unlikely to be a material standalone growth asset for a large pharmaceutical company.
What is the financial trajectory of amiloride hydrochloride?
The long-term financial trajectory is mature and defensive rather than growth-oriented.
| Period |
Market and financial characteristics |
| Original launch period |
Branded development and protected commercial sales |
| Genericization period |
Entry by multiple manufacturers and rapid price compression |
| Mature generic period |
Stable clinical demand, low unit economics, limited revenue growth |
| Current market |
Commodity supply, intermittent availability risk, minimal patent value |
| Forward outlook |
Flat to modestly declining demand with possible episodic price increases during shortages |
Revenue exposure is distributed across generic manufacturers. No major company is known to disclose amiloride hydrochloride as a separately material revenue line. The product therefore has little value as a branded licensing asset, but it may have portfolio value for a generic company seeking:
- A low-complexity oral solid-dose product
- A complete diuretic portfolio
- Additional pharmacy and hospital formulary access
- Manufacturing utilization
- Cross-selling opportunities with hydrochlorothiazide products
- A product with established clinical familiarity
The main financial risk is not loss of exclusivity. It is margin erosion combined with rising costs for active pharmaceutical ingredient, labor, compliance, packaging, and quality testing.
What competitive factors affect the amiloride hydrochloride market?
Amiloride competes clinically with other potassium-sparing diuretics and indirectly with broader antihypertensive therapies.
| Competitor |
Competitive relationship |
| Spironolactone |
More widely used in heart failure, resistant hypertension, and hyperaldosteronism; has endocrine adverse effects |
| Eplerenone |
More selective mineralocorticoid receptor antagonist; generally more expensive |
| Triamterene |
Alternative potassium-sparing diuretic |
| Hydrochlorothiazide |
Common diuretic, usually increases potassium loss |
| Chlorthalidone |
Longer-acting thiazide-like diuretic |
| Loop diuretics |
Stronger diuresis for edema and volume overload |
| ACE inhibitors and ARBs |
Often preferred for hypertension and cardiorenal indications |
Amiloride retains a niche where prevention or correction of potassium loss is clinically important. It is also used in selected patients with renal tubular sodium-handling disorders, although prescribing patterns vary by indication and market.
The product’s competitive weakness is limited potency as a stand-alone diuretic. Its strength is potassium conservation and its low acquisition cost.
What formulation patents protect amiloride hydrochloride?
Standard immediate-release amiloride hydrochloride tablets have no evident commercially significant formulation patent barrier. The ordinary tablet does not rely on an advanced delivery system, long-acting technology, transdermal platform, depot formulation, or device.
Potential formulation-related barriers would involve:
- Modified-release tablets
- New fixed-dose combinations
- Taste-masked or dispersible products
- Pediatric formulations
- Novel excipient systems
- Abuse-deterrent or targeted-delivery technology
These are not central to the current U.S. amiloride hydrochloride market. The established product is a conventional oral solid dose.
Are there Paragraph IV challenges for amiloride hydrochloride?
Paragraph IV litigation is not a meaningful current market driver for standard amiloride hydrochloride tablets because the original exclusivity period has expired. Paragraph IV certification is most commercially important when an ANDA applicant seeks approval before expiration of an Orange Book-listed patent.
For amiloride hydrochloride:
- Generic entry occurred long ago.
- Patent-based launch timing is no longer central.
- Litigation risk is low relative to newer branded drugs.
- ANDA approval and manufacturing readiness are more important than patent certification strategy.
A litigation event could still arise from a newly listed patent on an unusual formulation or combination product, but that would not normally affect the established generic tablet market.
What manufacturing and supply risks affect amiloride hydrochloride?
Manufacturing economics are more important than intellectual property. Low-priced generic drugs can experience supply disruption when only a few active manufacturers remain or when production costs exceed achievable market prices.
Key risks include:
- Concentrated API sourcing
- Batch failures
- FDA warning letters or import alerts
- Contract-manufacturer changes
- Low inventory incentives
- Packaging component shortages
- Wholesaler channel disruptions
- Product discontinuation after sustained price compression
For purchasers, supplier redundancy and reliable allocation may have greater value than nominal price. A temporary shortage can produce price volatility even when the long-term market remains structurally oversupplied.
Does amiloride hydrochloride have biosimilar risk?
No. Biosimilar competition does not apply because amiloride hydrochloride is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic substitution, not biosimilar entry.
This distinction matters commercially. Generic competition is governed principally by ANDA approval and therapeutic equivalence. Biosimilar competition involves reference-product exclusivity, biologic interchangeability, manufacturing complexity, and distinct FDA regulatory requirements.
What licensing deals involve amiloride hydrochloride?
No major recent licensing transaction is publicly associated with amiloride hydrochloride as a standalone strategic asset. The product’s low price and mature generic status make royalty-bearing licensing unattractive unless a transaction includes:
- A broader cardiovascular portfolio
- A regional distribution agreement
- A manufacturing or supply contract
- A fixed-dose combination
- A branded-generic platform
- A hospital or government procurement arrangement
Any transaction value would likely arise from distribution, supply continuity, or portfolio consolidation rather than from patent rights.
What generic launch scenarios exist for amiloride hydrochloride?
A new generic entrant would face limited patent risk but challenging economics.
| Launch scenario |
Commercial outcome |
| Lowest-cost supplier |
Possible volume gain but weak margin |
| Reliable shortage supplier |
Temporary pricing and market-share opportunity |
| Combination-product entrant |
Greater differentiation than single-agent tablets |
| Hospital-focused supplier |
Potential contract access and stable institutional demand |
| Branded-generic launch |
Limited pricing upside without clinical differentiation |
| Specialty formulation launch |
Higher development cost and uncertain demand |
A standard tablet launch is unlikely to support premium pricing. The strongest opportunity would come from a supply-constrained market, an underserved strength, or a differentiated combination product.
How strong is the patent estate for amiloride hydrochloride?
The patent estate is weak for commercial purposes. Amiloride hydrochloride has:
- No meaningful remaining composition-of-matter protection
- No apparent exclusivity-based pricing power
- No biosimilar barrier
- No central device or delivery-system protection
- Limited value in patent-backed licensing
- High dependence on manufacturing execution
The product can remain commercially useful despite a weak patent estate because clinical demand is established and the product is inexpensive. Its value is operational rather than intellectual-property driven.
Key Takeaways
- Amiloride hydrochloride is a mature generic potassium-sparing diuretic.
- FDA exclusivity and original patent protection have expired.
- Standard tablets face no material patent barrier to generic competition.
- Orange Book and ANDA status matter more than patent litigation.
- Standalone product revenue is not generally disclosed by manufacturers.
- Financial performance is likely stable to declining, with low margins.
- Supply reliability, API sourcing, and manufacturing compliance are the main risks.
- Spironolactone, eplerenone, triamterene, and other diuretics define the competitive environment.
- Biosimilar risk is irrelevant.
- Licensing value is limited unless tied to supply, distribution, or a combination product.
FAQs
Is amiloride hydrochloride still manufactured in the United States?
Generic manufacturers and distributors continue to supply amiloride hydrochloride products, but the active supplier list can change because of discontinuations, ANDA transfers, and contract-manufacturing arrangements. FDA NDC and drug-listing records provide the relevant current status.[3]
Can a company obtain an exclusive license for amiloride hydrochloride?
An exclusive license to the old active ingredient would have little value because original exclusivity has expired. Commercial exclusivity could arise only from a new protected formulation, combination, manufacturing process, or distribution arrangement.
Is amiloride hydrochloride profitable for generic-drug companies?
It can be profitable when produced efficiently and sold at sufficient volume, but it is unlikely to produce high margins. Profitability depends on API cost, manufacturing utilization, procurement contracts, and market supply conditions.
Does amiloride hydrochloride qualify for 180-day generic exclusivity?
A historical first-ANDA applicant could have pursued 180-day exclusivity if the statutory requirements were satisfied at the time. That issue is not commercially relevant to the mature market currently supplying standard amiloride hydrochloride tablets.
Could amiloride hydrochloride prices rise despite having no patents?
Yes. Generic prices can rise during shortages, supplier exits, quality events, API constraints, or channel disruptions. Such increases reflect supply conditions rather than patent exclusivity.
References
-
U.S. Food and Drug Administration. (n.d.). Midamor (amiloride hydrochloride) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). National Drug Code directory. https://www.accessdata.fda.gov/scripts/cder/ndc/
